Pediatric Bacterial Meningitis Surveillance in Niger: Increased Importance of Neisseria meningitidis Serogroup C, and a Decrease in Streptococcus pneumoniae Following 13-Valent Pneumococcal Conjugate Vaccine Introduction

被引:10
|
作者
Hama, Mamadou Kourna [1 ]
Khan, Dam [2 ]
Laouali, Boubou [1 ]
Okoi, Catherine [2 ]
Yam, Abdoulaye [3 ]
Haladou, Moussa [3 ]
Worwui, Archibald [2 ]
Ndow, Peter Sylvanus [2 ]
Obama, Ricardo Nse [3 ]
Mwenda, Jason M. [4 ]
Biey, Joseph [4 ]
Ntsama, Bernard [5 ]
Kwambana-Adams, Brenda A. [2 ]
Antonio, Martin [2 ,6 ]
Senghore, Madikay
Usuf, Effua
Uzochukwu, Egere
Zaman, Akram
Gehre, Florian
Tientcheu, Leopold
Mohammed, Nuredin Ibrahim
Dube, Felix
Ndow, Peter
Sambou, Suso
Jarju, Sheikh
Khan, Dam [2 ]
Chinelo, Ebruke
Bancroft, Rowan
机构
[1] Lab Hop Natl Niamey, Niamey, Niger
[2] London Sch Hyg & Trop Med, Med Res Council Unit Gambia, Collaborating Ctr New Vaccines Surveillance, WHO, London, England
[3] WHO Country Off, Niamey, Niger
[4] WHO Reg Off Africa, Brazzaville, Rep Congo
[5] WHO Intercountry Support Team West Africa, Ouagadougou, Burkina Faso
[6] Univ Warwick, Warwick Med Sch, Microbiol & Infect Unit, Coventry, W Midlands, England
关键词
meningitis; Niger; cerebrospinal fluid; N; meningitidis; S; pneumoniae; HAEMOPHILUS-INFLUENZAE; ANTIMICROBIAL RESISTANCE; MENINGOCOCCAL SEROGROUP; PHYLOGENETIC ANALYSIS; DISEASE; EPIDEMIC; OUTBREAK; NIAMEY; ASSAY; TOOL;
D O I
10.1093/cid/ciz598
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Meningitis is endemic in Niger. Haemophilus influenzae type b (Hib) vaccine and the 13-valent pneumococcal conjugate vaccine (PCV13) were introduced in 2008 and 2014, respectively. Vaccination campaign against Neisseria meningitidis serogroup A was carried out in 2010-2011. We evaluated changes in pathogen distribution using data from hospital-based surveillance in Niger from 2010 through 2016. Methods. Cerebrospinal fluid (CSF) specimens from children <5 years old with suspected meningitis were tested to detect vaccine-preventable bacterial pathogens. Confirmatory identification and serotyping/grouping of Streptococcus pneumoniae, N. meningitidis, and H. influenzae were done. Antimicrobial susceptibility testing and whole genome sequencing were performed on S. pneumoniae isolates. Results. The surveillance included 2580 patients with suspected meningitis, of whom 80.8% (2085/2580) had CSF collected. Bacterial meningitis was confirmed in 273 patients: 48% (131/273) was N. meningitidis, 45% (123/273) S. pneumoniae, and 7% (19/273) H. influenzae. Streptococcus pneumoniae meningitis decreased from 34 in 2014, to 16 in 2016. PCV13 serotypes made up 88% (7/8) of S. pneumoniae meningitis prevaccination and 20% (5/20) postvaccination. Neisseria meningitidis serogroup C (NmC) was responsible for 59% (10/17) of serogrouped N. meningitidis meningitis. Hib caused 67% (2/3) of the H. influenzae meningitis isolates serotyped. Penicillin resistance was found in 16% (4/25) of S. pneumoniae isolates. Sequence type 217 was the most common lineage among S. pneumoniae isolates. Conclusions. Neisseria meningitidis and S. pneumoniae remain important causes of meningitis in children in Niger. The decline in the numbers of S. pneumoniae meningitis post-PCV13 is encouraging and should continue to be monitored. NmC is the predominant serogroup causing N. meningitidis meningitis.
引用
收藏
页码:S133 / S139
页数:7
相关论文
共 50 条
  • [41] 13-valent Pneumococcal Conjugate Vaccine Given With Meningococcal C-Tetanus Toxoid Conjugate and Other Routine Pediatric Vaccinations: Immunogenicity and Safety
    Martinon-Torres, Federico
    Gimenez-Sanchez, Francisco
    Gurtman, Alejandra
    Bernaola, Enrique
    Diez-Domingo, Javier
    Carmona, Alfonso
    Sidhu, Mohinder
    Sarkozy, Denise A.
    Gruber, William C.
    Emini, Emilio A.
    Scott, Daniel A.
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2012, 31 (04) : 392 - 399
  • [42] Epidemiology of hospitalised paediatric community-acquired pneumonia and bacterial pneumonia following the introduction of 13-valent pneumococcal conjugate vaccine in the national immunisation programme in Japan
    Takeuchi, N.
    Naito, S.
    Ohkusu, M.
    Abe, K.
    Shizuno, K.
    Takahashi, Y.
    Omata, Y.
    Nakazawa, T.
    Takeshita, K.
    Hishiki, H.
    Hoshino, T.
    Sato, Y.
    Ishiwada, N.
    EPIDEMIOLOGY AND INFECTION, 2020, 148
  • [43] Dose-specific Effectiveness of 7-and 13-Valent Pneumococcal Conjugate Vaccines Against Vaccine-serotype Streptococcus pneumoniae Colonization in Children
    Lewnard, Joseph A.
    Givon-Lavi, Noga
    Dagan, Ron
    CLINICAL INFECTIOUS DISEASES, 2020, 71 (08) : E289 - E300
  • [44] The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A
    Cooper, David
    Yu, Xinhong
    Sidhu, Mohinder
    Nahm, Moon H.
    Fernsten, Philip
    Jansen, Kathrin U.
    VACCINE, 2011, 29 (41) : 7207 - 7211
  • [45] Streptococcus pneumoniae carriage among healthy and sick pediatric patients before the generalized implementation of the 13-valent pneumococcal vaccine in Morocco from 2010 to 2011
    Jroundi, Imane
    Mahraoui, Chafik
    Benmessaoud, Rachid
    Moraleda, Cinta
    Munoz Almagro, Carmen
    Seffar, Meryem
    Tligui, Houssain
    Kettani, Selma C.
    Benjelloun, Badr S.
    Alonso, Pedro L.
    Bassat, Quique
    JOURNAL OF INFECTION AND PUBLIC HEALTH, 2017, 10 (02) : 165 - 170
  • [46] Distribution of 13-Valent pneumococcal conjugate vaccine serotype streptococcus pneumoniae in adults 50Years and Older presenting with community-acquired pneumonia in Israel
    Regev-Yochay, Gili
    Chowers, Michal
    Chazan, Bibiana
    Gonzalez, Elisa
    Gray, Sharon
    Zhang, Zhou
    Pride, Michael
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2018, 14 (10) : 2527 - 2532
  • [47] Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children &lt;5 years: An active prospective nationwide surveillance
    Ben-Shimol, Shalom
    Greenberg, David
    Givon-Lavi, Noga
    Schlesinger, Yechiel
    Somekh, Eli
    Aviner, Shraga
    Miron, Dan
    Dagan, Ron
    VACCINE, 2014, 32 (27) : 3452 - 3459
  • [48] Continuous Effectiveness of Pneumococcal 13-Valent Conjugate Vaccine on Pediatric Pneumococcal Otomastoiditis: Results of 15 Years of Active/Prospective Surveillance in a Mexican Hospital on the Mexico-US Border
    Chacon-Cruz, Enrique
    Lopatynsky, Erika Z.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (08)
  • [49] Serotype distribution of invasive Streptococcus pneumoniae in adults 65 years of age and over after the introduction of childhood 13-valent pneumococcal conjugate vaccination programs in Canada, 2010-2016
    Demczuk, Walter H. B.
    Martin, Irene
    Desai, Shalini
    Griffith, Averil
    Caron-Poulin, Laurence
    Lefebvre, Brigitte
    McGeer, Allison
    Tyrrell, Gregory J.
    Zhanel, George G.
    Gubbay, Jonathan
    Hoang, Linda
    Levett, Paul N.
    Van Caeseele, Paul
    Gad, Rita Raafat
    Haldane, David
    Zahariadis, George
    German, Gregory
    Bernier, Jennifer Daley
    Strudwick, Lori
    Mulvey, Michael R.
    VACCINE, 2018, 36 (31) : 4701 - 4707
  • [50] Rise of multidrug-resistant Streptococcus pneumoniae clones expressing non-vaccine serotypes among children following introduction of the 10-valent pneumococcal conjugate vaccine in Bulgaria
    Setchanova, L.
    Alexandrova, A.
    Pencheva, D.
    Shakov, I
    Mihova, K.
    Kaneva, R.
    Mitov, I
    JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2018, 15 : 6 - 11